300639 Guangdong Hybribio Biotech
- 5.80
- -0.14-2.36%
Guangdong Hybribio Biotech News
Hybribio Biotech Unit Gets Nod to Market Deafness Gene Detection Kit in China
Guangdong Hybribio Biotech (SHE:300639) subsidiary Guangzhou Hybribio Medical Technology obtained a medical device registration certificate from China's National Medical Products Administration for it
Capbio (300639.SZ) plans to pay 0.65 yuan for 10 shares to be deducted from interest on May 23
CapBio (300639.SZ) announced that the company's 2023 dividend payment plan: for every 10 shares to all shareholders...
Capbio (300639.SZ): The repurchase was completed and the total cost was 30.108 million yuan to repurchase 4.445 million shares
Gelonghui, May 7, 丨 Capcom Biotech (300639.SZ) announced that as of the announcement disclosure date, the share repurchase plan had been implemented. The actual repurchase period was from February 6, 2024 to February 21, 2024. The cumulative number of shares repurchased was 4.445 million shares, accounting for 0.69% of the company's total share capital. The maximum transaction price was RMB 7.42 yuan/share, and the minimum transaction price was RMB 5.84 yuan/share. The total transaction amount was RMB 30.108 million (including transaction fees).
Capbio (300639.SZ): Net loss of 14.354,800 yuan in the first quarter
On April 26, Ge Longhui (300639.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 183 million yuan, a year-on-year decrease of 39.39%; net profit attributable to shareholders of listed companies - 14.3548 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 15.953 million yuan; basic earnings per share - 0.02 yuan.
Capbio (300639.SZ): 2023 net profit of 140 million yuan, plans to distribute 10 to 0.65 yuan
On April 23, Ge Longhui (300639.SZ) announced its 2023 annual report. Operating revenue for the reporting period was 1.04 billion yuan, down 80.27% year on year; net profit attributable to shareholders of listed companies was 140 million yuan, down 91.86% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 113 million yuan, down 93.47% year on year; it plans to distribute a cash dividend of 0.65 yuan (tax included) for every 10 shares to all shareholders.
Capbio (300639.SZ): No nuclear radiation-related tests on humans or saltwater fish and shrimp
Gelonghui, April 8, 丨 Kepu Biotech (300639.SZ) said on the investor interactive platform that the company is a leading integrated provider of molecular diagnostic products and services. It independently develops, produces and sells a series of testing products and related molecular diagnostic instruments in the field of infectious and hereditary diseases, including tumor testing, maternal and child health, birth defects, infectious diseases, individualized medication, etc. Related products are widely used in hospital clinical diagnosis, large-scale seawater population screening, public health prevention and control. There is no testing related to human or fish nuclear radiation.
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 25% over the past three months, it is easy to disregard Guangdong Hybribio BiotechLtd (SZSE:300639). But if you pay close attention, you might find that its key financial indicat
Guangdong Hybribio Biotech, Subsidiary Get Patent From Brazil for Isolation Method
Guangdong Hybribio Biotech (SHE:300639) and its subsidiary, Guangzhou Hybribio Biotech, received an invention patent certificate from Brazil's national industrial property authority for one of its inv
Capbio (300639.SZ): Obtained a Brazilian invention patent certificate
Gelonghui, March 21丨Capbio (300639.SZ) announced that recently, Guangdong Kepu Biotechnology Co., Ltd. and its wholly-owned subsidiary Guangzhou Kaipu Pharmaceutical Technology Co., Ltd. obtained an invention patent certificate issued by Brazil's National Industrial Property Office as a method for isolating placental trophoblasts from pregnant women's cervical desquamation cells.
Capbio (300639.SZ): “An Event-Driven MCU Operating System Implementation Method” obtained an invention patent
Gelonghui, March 7, 丨 Kepu Biotech (300639.SZ) announced that recently, Guangdong Kepu Biotechnology Co., Ltd., its wholly-owned subsidiaries Guangzhou Kepu Biotechnology Co., Ltd. (“Guangzhou KEP”), and Guangdong Kepu Intelligent Manufacturing Co., Ltd. (“CAPE Intelligent Manufacturing”) received the “Notice of Granting Patent Rights for Inventions” issued by the State Intellectual Property Office, which is an event-based MCU operating system implementation method.
Hybribio Calls for Raising International HPV Awareness
Capbio (300639.SZ): 0.69% of shares have been repurchased cumulatively
Glonghui, March 1, 丨 CapBio (300639.SZ) announced that as of February 29, 2024, the company has repurchased 4,445,000 shares, accounting for 0.69% of the company's current total share capital (not deducting shares in the company's special securities account); the highest transaction price for the repurchase was RMB 7.42 yuan/share, and the minimum transaction price was RMB 5.84 per share; the total amount of capital paid was RMB 30,100,843.49 (including transaction fees).
Hybribio Biotech's Unit Secures Registration Certificate for Nucleic Acid Analysis System
Guangdong Hybribio Biotech's (SHE:300639) unit, Guangdong Kaipu Technology Intelligent Manufacturing, received a medical device registration certificate for its fully automatic nucleic acid detection
Capcom Biotech (300639.SZ) subsidiary obtained a medical device registration certificate
Zhitong Finance App News, CapBio (300639.SZ) announced that Guangdong Kaipu Technology Intelligent Manufacturing Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the “Medical Device Registration Certificate (in vitro diagnostic reagent)” issued by the State Drug Administration. The product name is: Fully automatic nucleic acid detection and analysis system (model: HBQW-3200A).
Capbio (300639.SZ): Initial repurchase of 1.571,700 shares involving 10.02 million yuan
Gelonghui, Feb. 6, 丨 KP Biotech (300639.SZ) announced that on February 6, 2024, the company repurchased the company's shares for the first time through a dedicated share repurchase securities account. The number of shares repurchased was 1,571,700 shares, accounting for 0.24% of the company's current total share capital (without deducting shares in the company's special securities account); the highest transaction price for the repurchase was RMB 6.69 yuan/share. The minimum transaction price was RMB 5.84 yuan/share, and the total capital paid was RMB 10.02 million (excluding transaction fees).
Capbio (300639.SZ): Plans to spend 30 million yuan to 60 million yuan to buy back the company's shares
Gelonghui, Feb. 5 | CapBio (300639.SZ) announced that the company plans to use its own funds to repurchase some of the company's shares through centralized bidding transactions. The repurchase of shares will be used to protect the company's value and shareholders' rights. Use your own capital not less than RMB 30 million (inclusive) and not more than RMB 60 million (inclusive) to make a repurchase. Share repurchase price: no more than RMB 10.00 per share (inclusive). Based on the upper limit of the repurchase price and the upper and lower limit of the repurchase amount, the estimated number of shares to be repurchased is 3 million to 6 million shares, accounting for 0.46% of the company's total issued share capital
The Total Return for Guangdong Hybribio BiotechLtd (SZSE:300639) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) shareholders have seen the share price descend 27% over the month. But that doesn't change the fact that the returns over the last five years have
Capbio (300639.SZ): 2023 net profit pre-reduced by 89.57%-92.00%
Gelonghui, January 29丨Capcom Biotech (300639.SZ) announced its 2023 annual performance forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 13800.00 million yuan to 18.0000 million yuan, down 92.00%-89.57% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 11.95 million yuan - 16.15 million yuan, down 93.11% to 90.69% from the same period last year. During the reporting period, the company's net profit declined year-on-year, mainly due to changes in industry demand, related to the company
Capcom Biotech (300639.SZ): The total number of shareholders on January 19, 2024 was 35,862
Gelonghui, January 22丨CapBio (300639.SZ) said on the investor interactive platform that the total number of shareholders in the latest phase of the company, January 19, 2024, was 35,862.
CAPBIOLOGICAL (300639.SZ): The technology centers of CAP-CHEMICAL and CAP-PHARM were recognized as provincial enterprise technology centers
Glonghui on December 18丨Capcom Biotech (300639.SZ) announced that Chaozhou Kaipu Biochemical Co., Ltd. (“Kaipu Chemical”), a wholly-owned subsidiary of the company, and Guangzhou Kaipu Pharmaceutical Technology Co., Ltd. (“Kaipu Pharmaceutical”) recently received the “Notice on Issuing the 22nd Batch of Provincial Enterprise Technology Center Accreditation List” issued by the Guangdong Provincial Department of Industry and Information Technology, and learned that the technology centers of Kaipu Chemical and Kaipu Pharmaceutical were recognized as “provincial enterprise technology centers”.
Analysis
Price Target
No Data
